文献速递细菌感染、耐药与抗菌药物

短疗程庆大霉素辅助经验性治疗严重脓毒症与脓毒性休克的前瞻性观察队列研究

Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Study.
PubMed 文献 · Clin Infect Dis · 2017-01-01

该研究在荷兰两个ICU前瞻性纳入648例严重脓毒症或脓毒性休克患者,其中245例接受中位2天的庆大霉素辅助治疗。校正分析显示庆大霉素使用与肾衰竭风险增加相关(OR 1.39,95%CI 1.00-1.94),但未显著改善休克逆转或14天死亡率。在低耐药流行环境下,短疗程经验性庆大霉素辅助治疗未显示临床获益。

要点

  • 短疗程庆大霉素辅助治疗与肾衰竭风险增加相关(OR 1.39,95%CI 1.00-1.94)。
  • 庆大霉素未显著加快休克逆转(OR 1.34,95%CI 0.96-1.86)或降低14天死亡率(OR 1.41,95%CI 0.94-2.12)。
  • 在低耐药流行环境下,经验性庆大霉素辅助治疗未显示临床获益。

核心结论

  • 在低耐药流行环境中,短疗程经验性庆大霉素辅助治疗与肾衰竭发生率增加相关,但未加快休克逆转或改善生存。

研究设计与样本

  • 前瞻性观察性队列研究,2011至2015年在荷兰2个ICU连续纳入648例严重脓毒症或脓毒性休克患者。

主要发现

  • 648例中245例接受庆大霉素,中位疗程2天(IQR 1-3天);医院A使用率72%(222/309),医院B为7%(23/339)。
  • 校正后庆大霉素使用与肾衰竭的OR为1.39(95%CI 1.00-1.94),与休克持续时间的OR为1.34(95%CI 0.96-1.86),与14天死亡率的OR为1.41(95%CI 0.94-2.12)。

临床怎么用

  • 在低耐药流行区,严重脓毒症或脓毒性休克患者经验性短疗程加用庆大霉素需权衡肾衰竭风险,未显示休克逆转或生存获益。

局限性

  • 研究为观察性设计,庆大霉素使用非随机分配,可能存在适应证混杂。
  • 结果来自低耐药流行环境,外推至高耐药地区需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND.: Metaanalyses failed to demonstrate clinical benefits of beta lactam plus aminoglycoside combination therapy compared to beta lactam monotherapy in patients with sepsis. However, few data exist on the effects of short-course adjunctive aminoglycoside therapy in sepsis patients with organ failure or shock. METHODS.: We prospectively enrolled consecutive patients with severe sepsis or septic shock in 2 intensive care units in the Netherlands from 2011 to 2015. Local antibiotic protocols recommended empirical gentamicin add-on therapy in only 1 of the units. We used logistic regression analyses to determine the association between gentamicin use and the number of days alive and free of renal failure, shock, and death, all on day 14. RESULTS.: Of 648 patients enrolled, 245 received gentamicin (222 of 309 [72%] in hospital A and 23 of 339 [7%] in hospital B) for a median duration of 2 days (interquartile range, 1-3). The adjusted odds ratios associated with gentamicin use were 1.39 (95% confidence interval [CI], 1.00-1.94) for renal failure, 1.34 (95% CI, 0.96-1.86) for shock duration, and 1.41 (95% CI, 0.94-2.12) for day-14 mortality. Based on in vitro susceptibilities, inappropriate (initial) gram-negative coverage was given in 9 of 245 (4%) and 18 of 403 (4%) patients treated and not treated with gentamicin, respectively (P = .62). CONCLUSIONS.: Short-course empirical gentamicin use in patients with sepsis was associated with an increased incidence of renal failure but not with faster reversal of shock or improved survival in a setting with low prevalence of antimicrobial resistance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ong DSY, Frencken JF, Klein Klouwenberg PMC, et al. Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Study. Clin Infect Dis. 2017. PMID: 28329088. doi:10.1093/cid/cix186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。